In The News

Ropes & Gray Advises CANbridge Pharmaceuticals in Greater China Licensing Agreement

Practices: Life Sciences, Intellectual Property, Intellectual Property Transactions, Health Care Finance & Restructuring, China Life Sciences, Asia Pacific, Strategic Licensing Programs, Strategic Commercial Agreements, International IP/Tech Transactions, Life Sciences Mergers & Acquisitions, Life Sciences Emerging Companies & Venture Capital

Ropes & Gray advised biopharmaceutical firm CANbridge Pharmaceuticals Inc. in an exclusive licensing agreement in China with GC Pharma, a South Korea-based company and one of the world’s largest protein products manufacturers, to commercialize Hunterase, a human recombinant iduronate-2 –sulfatase enzyme replacement therapy for the treatment of Hunter syndrome. The deal was announced on Jan 7.

Developed by GC Pharma, Hunterase is marketed in more than ten countries. There is no approved treatment for rare disease Hunter syndrome in China, unlike in some other nations.

The Ropes & Gray team included IP transactions partner Geoffrey Lin, IP transactions counsel David Chen (both of Shanghai), IP transactions partner Mark Bellomy (Boston), and life sciences partner Katherine Wang (Shanghai).

Cookie Settings